Drugs & Aging

, Volume 19, Issue 11, pp 865–877 | Cite as

Role of Hormones in the Pathogenesis and Management of Sarcopenia

Review Article


There is growing evidence to indicate that age-related declines in growth hormone (GH), insulin-like growth factor (IGF)-1, and androgen and estrogen production play a role in the pathogenesis of sarcopenia (an age-related decline in muscle mass and quality). Although GH supplementation has been reported to increase lean body mass in elderly individuals, the high incidence of adverse effects combined with a very high cost has limited the applicability of this form of therapy. The assessment of an alternative approach to enhance the GH/IGF-1 axis in the elderly by using GH-releasing hormone and other secretagogues is currently under way and is showing some promise. Testosterone replacement therapy may increase muscle mass and strength and decrease body fat in hypogonadal elderly men. Long-term randomised, controlled trials are needed, however, to better define the risk-benefit ratio of this form of therapy before it can be recommended. Available data are currently insufficient to decide what role estrogen replacement therapy may play in the management of sarcopenia.

Therefore, although the evidence linking age-related hormonal changes to the development of sarcopenia is rapidly growing, it is still too early to determine the clinical utility of hormonal supplementation in the management of sarcopenia.



The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.


  1. 1.
    Baumgartner RN, Stauber PM, McHugh D, et al. Cross-sectional age differences in body composition in persons 60+ years of age. J Gerontol A Biol Sci Med Sci 1995; 50: M307–16PubMedCrossRefGoogle Scholar
  2. 2.
    Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997; 127: 990S–1SPubMedGoogle Scholar
  3. 3.
    Kotler DP. Cachexia. Ann Intern Med 2000; 133: 622–34PubMedGoogle Scholar
  4. 4.
    Roubenoff R. The pathophysiology of wasting in the elderly. J Nutr 1999; 129: 256S–9SPubMedGoogle Scholar
  5. 5.
    Alexander NB, Schultz A, Warwick DN. Rising from a chair: effects of age and functional ability on performance biomechanics. J Gerontol 1991; 46: M91–8PubMedCrossRefGoogle Scholar
  6. 6.
    Hubert HB, Bloch DA, Fries JF. Risk factors for physical disability in an aging cohort: the NHANES 1 epidemiologic follow-up study. J Rheumatol 1993; 20: 480–8PubMedGoogle Scholar
  7. 7.
    Guralink JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49: M85–94CrossRefGoogle Scholar
  8. 8.
    Kritz-Silverstein D, Barrett-Conner E. Grip strength and bone mineral density in older women. J Bone Miner Res 1994; 9: 45–52PubMedCrossRefGoogle Scholar
  9. 9.
    Toner MM, Sawka MN, Foley ME, et al. Effects of body mass and morphology on thermal responses in water. J Appl Physiol 1986; 60: 521–5PubMedCrossRefGoogle Scholar
  10. 10.
    Kohert WM, Kirwan JP, Staten MA, et al. Insulin resistance in aging is related to abdominal obesity. Diabetes 1993; 42: 273–81CrossRefGoogle Scholar
  11. 11.
    Dutta C, Hadley E. The significance of sarcopenia in old age. J Gerontol 1995; 50(A): 1–4Google Scholar
  12. 12.
    Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755–63PubMedCrossRefGoogle Scholar
  13. 13.
    Melton J, Khosla S, Crowson C, et al. Epidemiology of sarcopenia. J Am Geriatr Soc 2000; 48: 625–30PubMedGoogle Scholar
  14. 14.
    Navarro A, Lopez-Cepero JM, Sanchez del Pino MJ. Skeletal muscle and aging. Front Biosci 2001; 6: d26–44PubMedCrossRefGoogle Scholar
  15. 15.
    Allen TH, Anderson EC, Langham WH. Total body potassium and gross body composition in relationship to age. J Gerontol 1960; 15: 348–57PubMedCrossRefGoogle Scholar
  16. 16.
    Tzankoff SP, Norris AH. Effect of muscle mass decrease on age-related BMR changes. J Appl Physiol 1977; 43: 1001–6PubMedGoogle Scholar
  17. 17.
    Young A, Stokes M, Crowe M. Size and strength of the quadriceps muscles of old and young men. Clin Physiol 1985; 5: 145–54PubMedCrossRefGoogle Scholar
  18. 18.
    Young A, Stokes M, Crowe M. Size and strength of the quadriceps muscles of old and young women. Eur J Clin Invest 1984; 14: 282–7PubMedCrossRefGoogle Scholar
  19. 19.
    Imamura K, Ashida H, Ishikawa T, et al. Human major psoas muscle and sacrospinalis muscle in relation to age: a study by computed tomography. J Gerontol 1983; 38: 678–81PubMedCrossRefGoogle Scholar
  20. 20.
    Kligaard H, Mantoni M, Schianffino S, et al. Function, morphology and protein expression of aging skeletal muscle: a cross-sectional study of elderly men with different training backgrounds. Acta Physiol Scand 1990; 140: 119–39CrossRefGoogle Scholar
  21. 21.
    Overend TJ, Cunningham DA, Paterson DH, et al. Thigh composition in young and elderly men determined by computed tomography. Clin Physiol 1992; 12: 629–40PubMedCrossRefGoogle Scholar
  22. 22.
    Rice CL, Cunningham DA, Paterson DH, et al. Arm and leg composition determined by computed tomography in young and elderly men. Clin Physiol 1989; 9: 207–20PubMedCrossRefGoogle Scholar
  23. 23.
    Tomonaga M. Histochemical and ultrastructural changes in senile human skeletal muscle. J Am Geriatr Soc 1977; 25: 125–31PubMedGoogle Scholar
  24. 24.
    Jennekens FG, Tolinson BE, Walton J. Histochemical aspects of five limb muscles in old age: an autopsy study. J Neurol Sci 1971; 14: 259–76PubMedCrossRefGoogle Scholar
  25. 25.
    Balagopal P, Rooyackers OE, Adey DB, et al. Effects of aging on in vivo synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans. Am J Physiol 1997; 273: E790–800PubMedGoogle Scholar
  26. 26.
    Lexell J, Henriksson-Larsen K, Winblad B, et al. Distribution of different fiber types in human skeletal muscle: effects of aging studied in whole muscle-cross sections. J Appl Physiol 1985; 59: 1228–36PubMedGoogle Scholar
  27. 27.
    Jakobson F, Borg K, Edstrom L. Fiber-type composition, structure and cytoskeletal protein location of fibers in anterior tibial muscle: comparison between young adults and physically active aged humans. Acta Neuropathol 1990; 80: 459–69CrossRefGoogle Scholar
  28. 28.
    Doherty TJ, Brown WF. The estimated number and relative size of thenar motor units as selected by multiple point stimulation in young and older adults. Muscle Nerve 1993; 74: 868–74Google Scholar
  29. 29.
    Wanagat J, Cao Z, Pathare P, et al. Mitochondrial DNA deletion mutations co localize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia. FASEB J 2001; 15(2): 322–32PubMedCrossRefGoogle Scholar
  30. 30.
    Weindruch R. Interventions based on the possibility that oxidative stress contributes to sarcopenia. J Gerontol A Biol Sci Med Sci 1995; 50: 157–61PubMedGoogle Scholar
  31. 31.
    Doherty TJ, Vandervoort AA, Taylor AW, et al. Effects of aging on the motor unit: a brief review. Can J Appl Physiol 1992; 18: 331–58CrossRefGoogle Scholar
  32. 32.
    Tomlinson BE, Irving D. The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci 1977; 34: 213–9PubMedCrossRefGoogle Scholar
  33. 33.
    Welle S, Thornton T, Jozefowicz R, et al. Myofibrillar protein synthesis in young and old men. Am J Physiol 1993; 26: E693–8Google Scholar
  34. 34.
    Balagopal P, Rooyackers OE, Adey DB, et al. Effects of aging on in vivo synthesis of skeletal muscle myosine heavy-chain and sarcoplasmic protein in humans. Am J Physiol 1997; 273: E790–800PubMedGoogle Scholar
  35. 35.
    Clement FJ. Longitudinal and cross-sectional assessments of age changes in physical strength as related to sex, social class, and mental ability. J Gerontol 1974; 29: 423–9PubMedCrossRefGoogle Scholar
  36. 36.
    Larsson L, Grimby G, Karlsson J. Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 1979; 46: 451–6PubMedGoogle Scholar
  37. 37.
    Murray MP, Gardner GM, Mollinger LA, et al. Strength of isometric and isokinetic contractions. Phys Ther 1980; 60: 412–9PubMedGoogle Scholar
  38. 38.
    Johnson T. Age-related differences in isometric and dynamic strength and endurance. Phys Ther 1982; 62: 985–9PubMedGoogle Scholar
  39. 39.
    Viitasalo JT, Era P, Leskinen AL, et al. Muscular strength profiles and anthopometry in random samples of men aged 31–35, 5155, and 71–75 years. Ergonomics 1985; 28: 1563–74CrossRefGoogle Scholar
  40. 40.
    Frontera WR, Hughes VA, Lutz KJ, et al. A cross-sectional study of muscle strength and mass in 45–78-year-old men and women. J Appl Physiol 1991; 71: 644–50PubMedGoogle Scholar
  41. 41.
    Era P, Lyyra AL, Viitasalo JT, et al. Determinants of isometric muscle strength in men of different ages. Eur J Appl Physiol 1992; 64: 84–91CrossRefGoogle Scholar
  42. 42.
    Asmussen E, Heeboll-Nielsen K. Isometric muscle strength in relation to age in men and women. Ergonomics 1962; 5: 167–9CrossRefGoogle Scholar
  43. 43.
    Harries UJ, Bassey EJ. Torque-velocity relationships for the knee extensors in women in their 3rd and 7th decades. Eur J Appl Physiol 1990; 60: 187–90CrossRefGoogle Scholar
  44. 44.
    Maurray MP, Duthie Jr EH, Gambert SR, et al. Age-related differences in knee muscle strength in nominal women. J Gerontol 1985; 40: 275–80CrossRefGoogle Scholar
  45. 45.
    Young A, Stokes M, Crowe M. Size and strength of the quadriceps muscles of old and young women. Eur J Clin Invest 1984; 14: 282–7PubMedCrossRefGoogle Scholar
  46. 46.
    Stalberg E, Borges O, Ericsson M, et al. The quadriceps femoris muscle in 20–70-year-old subjects: relationships between knee extension torque electrophysiological parameters, and muscle fiber characteristics. Muscle Nerve 1989; 12: 382–9PubMedCrossRefGoogle Scholar
  47. 47.
    Aniansson A, Sperling L, Rundgren A, et al. Muscle function in 75-year-old men and women: a longitudinal study. Scand J Rehabil Med Suppl 1983; 9: 92–102PubMedGoogle Scholar
  48. 48.
    Aniansson A, Hedberg M, Henning GB, et al. Muscle morphology, enzymatic activity, and muscle strength in elderly men: a follow-up study. Muscle Nerve 1986; 9: 585–91PubMedCrossRefGoogle Scholar
  49. 49.
    Aniansson A, Grimby G, Hedberg N. Compensatory muscle fiber hypertrophy in elderly men. J Appl Physiol 1992; 73: 812–6PubMedGoogle Scholar
  50. 50.
    Bassey EJ, Harries UJ. Normal values for hand grip strength in 920 men and women aged over 65 years, and longitudinal changes over 4 years in 620 survivors. Clin Sci 1993; 84: 331–7PubMedGoogle Scholar
  51. 51.
    Tanaka H, Seals DR. Age and gender interactions in physiological functional capacity: insight form swimming performance. J Appl Physiol 1997; 82(3): 846–51PubMedGoogle Scholar
  52. 52.
    Dempsey JA, Seals DR. Aging, exercise and cardiopulmonary function. In: Lamb DR, Gisolfi CV, Nadel E, editors. Perspectives in exercise science and sports medicine: exercise in older adults. Carmel (IN): Cooper, 1995: 237–304Google Scholar
  53. 53.
    Joyner MJ. Physiological limiting factors and distance running: influence of gender and age on record performances. In: Holloszy JO, editor. Exercise and sport science reviews. Baltimore (MD): Williams & Wilkins, 1993: 103–33Google Scholar
  54. 54.
    Conley KE, Kemper WF, Crowther GJ. Limits to sustainable muscle performance: interaction between glycolysis and oxidative phosphorylation. J Exp Biol 2001; 204 (Pt 18): 3189–94PubMedGoogle Scholar
  55. 55.
    Conely KE, Esselman PC, Jubrias SA, et al. Ageing, muscle properties and maximal O(2) uptake rate in humans. J Physiol 2000; 526 Pt 1: 211–7CrossRefGoogle Scholar
  56. 56.
    Fiatarone MA, O’Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330: 1769–75PubMedCrossRefGoogle Scholar
  57. 57.
    Bendall MJ, Bassey EJ, Pearson MB. Factors affecting walking speed of elderly people. Age Ageing 1989; 18: 327–32PubMedCrossRefGoogle Scholar
  58. 58.
    Vellas B, Baumgartner RN, Wayne SJ, et al. Relationship between malnutrition and falls in the elderly. Nutrition 1992; 8: 105–8PubMedGoogle Scholar
  59. 59.
    Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol 2000; 55A(12): M716–24Google Scholar
  60. 60.
    Rudman D. Growth hormone, body composition, and aging. J Am Geriatr Soc 1985; 33: 800–1PubMedGoogle Scholar
  61. 61.
    Kelijman M. Age-related alterations of growth hormone/insulin-like-growth-factor I axis. J Am Geriatr Soc 1991; 39: 295–307PubMedGoogle Scholar
  62. 62.
    Jorgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; I: 1221–5CrossRefGoogle Scholar
  63. 63.
    Binnerts A, Deurenberg P, Swat GR, et al. Body composition in growth hormone-deficient adults. Am J Clin Nutr 1992; 55: 918–23PubMedGoogle Scholar
  64. 64.
    Debore H, Block GJ, Voerman HJ, et al. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance. J Clin Endocrinol Metab 1986; 75: 833–7Google Scholar
  65. 65.
    Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1–6PubMedCrossRefGoogle Scholar
  66. 66.
    Cohen L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-1 concentrations. Clin Endocrinol 1993; 39: 417–25CrossRefGoogle Scholar
  67. 67.
    Papadakis MA, Grady B, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996; 124: 708–16PubMedGoogle Scholar
  68. 68.
    Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991; 39: 235–40PubMedGoogle Scholar
  69. 69.
    Chu LW, Lam KS, Tam SC, et al. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients. J Clin Endocrinol Metab 2001; 86(5): 1913–20PubMedCrossRefGoogle Scholar
  70. 70.
    Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785–92PubMedCrossRefGoogle Scholar
  71. 71.
    Bengtsson B, Eden S, Lonn L, et al. Treatment of adults with growth hormone deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76(2): 309–31PubMedCrossRefGoogle Scholar
  72. 72.
    Lissett CA, Shalet SM. Effects of growth hormone on bone and muscle. Growth Horm IGF Res 2000; 10 Suppl. B: S95–101PubMedCrossRefGoogle Scholar
  73. 73.
    Iovino M, Monteleone P, Steardo L. Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging. J Clin Endocrinol Metab 1989; 69: 910–3PubMedCrossRefGoogle Scholar
  74. 74.
    Corpas E, Harman SM, Pineyro MA, et al. Growth hormone (GH)-releasing hormone-(1–29) twice daily reverses the decreased GH and insulin like growth factor-1 levels in old men. J Clin Endocrinol Metab 1992; 75: 530–5PubMedCrossRefGoogle Scholar
  75. 75.
    Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth facto I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81(12): 4249–57PubMedCrossRefGoogle Scholar
  76. 76.
    Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987; 8: 1–18PubMedCrossRefGoogle Scholar
  77. 77.
    Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-1 in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78(3): 744–52PubMedCrossRefGoogle Scholar
  78. 78.
    Hammerman MR. Insulin-like growth factors and aging. Endocrinol Metab Clin North Am 1987; 16(4): 995–1011PubMedGoogle Scholar
  79. 79.
    Arvat E, Broglio F, Ghigo E. Insulin-like growth factor 1. Drugs Aging 2000; 16(1): 29–40PubMedCrossRefGoogle Scholar
  80. 80.
    Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14(1): 20–39PubMedGoogle Scholar
  81. 81.
    Thissen J, Keteslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80–101PubMedGoogle Scholar
  82. 82.
    Johnson TR, Blossey BK, Denko CW, et al. Expression of insulin-like growth factor-1 in cultural rat hepatocytes: effects of insulin and growth hormone. Mol Endocrinol 1989; 3: 580–7PubMedCrossRefGoogle Scholar
  83. 83.
    Rutanen EM, Karkkainen T, Stenman UH, et al. Aging is associated with decreased suppression of insulin-like growth factor binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 2177–81CrossRefGoogle Scholar
  84. 84.
    Benbassat CA, Maki KC, Unterman TG. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 1997; 82(5): 1484–91PubMedCrossRefGoogle Scholar
  85. 85.
    Veldhuis JD, Bidlingmaier S, Anderson SM, et al. Lowering total plasma insulin-like growth factor 1 concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-Peg), augments the amplitude of GH secretary bursts and elevates basal/non-pulsatile GH release in healthy women and men. J Clin Endocrinol Metab 2001; 86(7): 3304–10PubMedCrossRefGoogle Scholar
  86. 86.
    Quinn LS, Haugk KL. Over expression of the type-1 insulin-like growth factor receptor increases ligand-dependent proliferation and differentiation in bovine skeletal myogenic cultures. J Cell Physiol 1996; 168(1): 34–41PubMedCrossRefGoogle Scholar
  87. 87.
    Schwartz RS. Trophic factor supplementation: effect on the age-associated changes in body composition. J Gerontol Series A 1995; 50A: 151–6CrossRefGoogle Scholar
  88. 88.
    Baumgartner R, Waters D, Gallgher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123–36PubMedCrossRefGoogle Scholar
  89. 89.
    Perry HM, Miller DK, Patrick P, et al. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 2000; 49(8): 1085–91PubMedCrossRefGoogle Scholar
  90. 90.
    Ashton WS, Degnan BM, Daniel A, et al. Testosterone increases insulin-like growth factor-1 and insulin-like growth factor-binding protein. Ann Clin Lab Sci 1995; 24: 381–8Google Scholar
  91. 91.
    Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269 (5 Pt 1): E820–6PubMedGoogle Scholar
  92. 92.
    Morley JE, Perry III M, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–52PubMedGoogle Scholar
  93. 93.
    Gentili A, Mulligan T, Godschalk M, et al. Unequal impact of short-term testosterone repletion on the somatotrophic axis of young and older men. J Clin Endocrinol Metab 2002; 87(2): 825–34PubMedCrossRefGoogle Scholar
  94. 94.
    Gray A, Feldman HA, Mckinlay J, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016–25PubMedCrossRefGoogle Scholar
  95. 95.
    Morley JE, Kaiser FE, Perry HM, et al. Longitudinal changes in testosterone, luteinizing hormone and follicle stimulating hormone in healthy older males. Metabolism 1997; 46: 410–4PubMedCrossRefGoogle Scholar
  96. 96.
    Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrin Metab 1992; 75: 1092–8CrossRefGoogle Scholar
  97. 97.
    Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relationship to impotence. J Clin Endocrinol Metab 1990; 71: 963–9PubMedCrossRefGoogle Scholar
  98. 98.
    Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82(6): 1661–7PubMedCrossRefGoogle Scholar
  99. 99.
    Snyder PJ, Peachey H, Hannoush P, et al. Effects of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(8): 2647–53PubMedCrossRefGoogle Scholar
  100. 100.
    Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85(8): 2839–53PubMedCrossRefGoogle Scholar
  101. 101.
    Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81(10): 3469–75PubMedCrossRefGoogle Scholar
  102. 102.
    Katznelson L, Finkelstein JS, Scheoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81(12): 4358–65PubMedCrossRefGoogle Scholar
  103. 103.
    Bakhshi V, Elliot M, Gentili M, et al. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc 2001; 48(5): 550–3Google Scholar
  104. 104.
    Ly LP, Jimernes M, Zhuang TN, et al. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001; 86(9): 4078–88PubMedCrossRefGoogle Scholar
  105. 105.
    Morley JE, Kaiser FE, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decrease in bioavailable testosterone, and dehydroepiandrosterone sulfate. Proc Natl Acad Sci U S A 1997; 94: 7537–42PubMedCrossRefGoogle Scholar
  106. 106.
    Abbasi A, Duthie EH, Sheldahl L, et al. Association of dehydroepiandrosterone sulfate, body composition, and physical fitness in independent community-dwelling older men and women. J Am Geriatr Soc 1998; 46: 263–73PubMedGoogle Scholar
  107. 107.
    Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998; 49: 421–32CrossRefGoogle Scholar
  108. 108.
    Baulieu E, Thomas G, Legarain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution ofthe DHEAge study to a sociomedical issue. Proc Natl Acad Sci U S A 2000; 97(8): 4279–84PubMedCrossRefGoogle Scholar
  109. 109.
    Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999; 84: 1527–33PubMedCrossRefGoogle Scholar
  110. 110.
    Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 1995; 123(9): 673–5PubMedGoogle Scholar
  111. 111.
    Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1997; 82: 1332–7PubMedCrossRefGoogle Scholar
  112. 112.
    Pottratz ST, Bellido T, Mocharla H, et al. 17 alpha estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest 1994; 93: 944–50PubMedCrossRefGoogle Scholar
  113. 113.
    Ralston SH. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. J Bone Miner Res 1994; 9: 883–90PubMedCrossRefGoogle Scholar
  114. 114.
    Veldhuis JD, Evans WS, Bowers CY, et al. Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2. Endocrine 2001; 14(1): 45–62PubMedCrossRefGoogle Scholar
  115. 115.
    Haarbo J, Marslew U, Gotfrdsen A, et al. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991; 40: 1323–6PubMedCrossRefGoogle Scholar
  116. 116.
    Gower BA, Nyman L. Association among oral estrogen use, free testosterone concentrations, and lean body mass among postmenopausal women. J Clin Endocrinol Metab 2000; 85: 4476–80PubMedCrossRefGoogle Scholar
  117. 117.
    Sorensen MB, Rosenfalck AM, Hojgaard L, et al. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 2001; 9(10): 622–6PubMedCrossRefGoogle Scholar
  118. 118.
    Dionne JI, Kinaman KA, Poehlman ET. Sarcopenia and muscle function during menopause and hormone-replacement therapy. J Nutr Health Aging 2000; 4(3): 156–61PubMedGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Hosam K. Kamel
    • 1
  • Diana Maas
    • 2
  • Edmund H. DuthieJr
    • 1
  1. 1.Division of Geriatrics, Department of MedicineMedical College of Wisconsin, and the Clement J. Zablocki VAMCMilwaukeeUSA
  2. 2.Division of Endocrinology, Department of MedicineMedical College of Wisconsin, and the Clement J. Zablocki VAMCMilwaukeeUSA

Personalised recommendations